Free tool
FAERS Monitor: Naprelan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020353 or its brand name (Naprelan, Naproxen Sodium). Reports on generic versions are filed under their own applications.
Reports
13,985
Serious
10,751
77% of reports
Hospitalization
6,092
Death reported
3,931
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective3,011
- fatigue2,757
- off label use2,620
- pain2,616
- rash2,391
- arthralgia2,341
- diarrhoea2,328
- vomiting2,269
- condition aggravated2,199
- joint swelling2,197
- synovitis2,148
- fibromyalgia2,142
- rheumatoid arthritis2,139
- dizziness2,102
- abdominal discomfort2,084
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 115 |
| 2005 | 159 |
| 2006 | 73 |
| 2007 | 57 |
| 2008 | 171 |
| 2009 | 123 |
| 2010 | 151 |
| 2011 | 374 |
| 2012 | 1,169 |
| 2013 | 248 |
| 2014 | 243 |
| 2015 | 318 |
| 2016 | 498 |
| 2017 | 512 |
| 2018 | 536 |
| 2019 | 769 |
| 2020 | 744 |
| 2021 | 674 |
| 2022 | 1,002 |
| 2023 | 1,153 |
| 2024 | 2,036 |
| 2025 | 2,056 |
| 2026 | 803 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,174 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| synovitisSignal | 2,148 | 203.2 | 194.9 | 380,945 |
| fibromyalgiaSignal | 2,142 | 145.2 | 139.4 | 279,968 |
| rheumatoid arthritisSignal | 2,139 | 28.9 | 27.7 | 56,724 |
| joint swellingSignal | 2,197 | 27.9 | 26.8 | 56,158 |
| abdominal discomfortSignal | 2,084 | 18.9 | 18.2 | 35,167 |
| condition aggravatedSignal | 2,199 | 10.9 | 10.5 | 20,017 |
| arthralgiaSignal | 2,341 | 8.5 | 8.2 | 15,731 |
| rashSignal | 2,391 | 8.3 | 8.0 | 15,558 |
| vomitingSignal | 2,269 | 7.3 | 7.0 | 12,525 |
| painSignal | 2,616 | 6.4 | 6.2 | 12,293 |
| dizzinessSignal | 2,102 | 6.4 | 6.1 | 9,681 |
| diarrhoeaSignal | 2,328 | 5.4 | 5.2 | 8,668 |
| fatigueSignal | 2,757 | 5.3 | 5.2 | 10,061 |
| off label useSignal | 2,620 | 4.5 | 4.4 | 7,443 |
| drug ineffectiveSignal | 3,011 | 3.4 | 3.3 | 5,549 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.